Shionogi & Co. Q2 Fiscal Year 2024 Earnings Call Summary

In the latest earnings call, Shionogi & Co. discussed its financial performance for the second quarter of Fiscal Year 2024, acknowledging a 7.2% decline in year-on-year revenue and a 22.2% decrease in operating profit. Despite these setbacks, the company remains focused on achieving record revenues and profits for the third consecutive year, targeting ¥4.6 trillion in revenue and ¥1.65 trillion in operating profit.

The company’s strategy revolves around growth in HIV royalties, overseas expansion, and domestic infectious disease management. Shionogi also highlighted a significant increase in royalty income, particularly from its HIV franchise, and strong growth in the over-the-counter (OTC) segment.

Key Takeaways

• Revenue Decline: Shionogi & Co. reported a year-on-year revenue decline of 7.2% and a 22.2% reduction in operating profit in Q2 of FY2024.
• Targets: The company aims to achieve record revenues and profits for the third year in a row, with targets set at ¥4.6 trillion for revenue and ¥1.65 trillion for operating profit.
• Growth Drivers: Key growth drivers include HIV royalties, overseas expansion, and domestic infectious disease management.
• Increased Earnings: There was a 26.6% increase in HIV franchise earnings and expansion in the OTC segment.
• COVID-19 Treatments: Shionogi plans to enhance its market share in COVID-19 treatments and increase treatment rates.
• Quality of Life (QOL) Diseases: The company is focusing on expanding its portfolio in QOL diseases, such as insomnia, and has increased its dividend to ¥87 per share.

Company Outlook

Shionogi is optimistic about meeting its second-half targets and maintaining momentum across various product segments. The company is aiming for a revenue goal of 460 billion yen by 2025 and considering strategic investments of 400 to 500 billion yen for future growth initiatives.

Challenges and Opportunities

Bearish Highlights: The company acknowledged weaknesses in bridging pharmacology from animal models to human applications and recognized the need for enhanced pharmacology capabilities.

Bullish Highlights: Shionogi reported stable sales in infectious diseases, generating 25 billion yen in the first half of the year despite a lack of influenza cases. Their dual approach in infectious and QOL diseases is expected to bolster sales teams and enhance digital engagement for growth.

Misses: Sales of the new product, Xocova, fell short of the ¥5 billion target due to low infection rates.

Q&A Highlights

Executives discussed projected quarterly growth of 13% to 14% and highlighted ongoing developments in their pipeline. The company has modified its mid-term forecast for 2030 upwards, expressing confidence in its long-acting injectable (LAI) treatments.

Shionogi & Co. remains committed to its growth strategy despite facing a challenging quarter. The company’s dedication to expanding its HIV franchise, enhancing its OTC segment, and improving treatment rates for COVID-19 and other infectious diseases underlines its proactive approach to overcoming obstacles. With strategic investments planned and a focus on bolstering its QOL disease portfolio, Shionogi is positioning itself for sustained growth in the coming years. Their R&D efforts and the introduction of new products like Xocova and Xofluza aim to demonstrate their commitment to innovation and market expansion.

Full Transcript Highlights

Yoshimasa Kyokawa: The Head of Public Relations at Shionogi began the meeting, introducing the executive team and outlining the agenda.

Isao Teshirogi: Shionogi's CEO discussed the company’s performance, emphasizing their commitment to growth despite the revenue and profit declines.

John Keller: Senior VP of R&D detailed the successes in the HIV segment and the ongoing development of their pipeline products.

Takeki Uehara: Senior VP shared updates on the acute respiratory infection business and the importance of diagnosis and treatment.

Toshinobu Iwasaki: VP discussed the domestic business strategies, emphasizing the need for increased treatment rates and educational outreach.

The session concluded with a Q&A segment, allowing analysts to inquire further into the company's strategies and future outlook.